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isenovic@yahoo.comAbstractObesity is associated with aberrant sodium/potassium-ATPase (NaC/KC-ATPase) activity,
apparently linked to hyperglycemic hyperinsulinemia, which may repress or inactivate the
enzyme. The reduction of NaC/KC-ATPase activity in cardiac tissue induces myocyte death
and cardiac dysfunction, leading to the development of myocardial dilation in animal
models; this has also been documented in patients with heart failure (HF). During several
pathological situations (cardiac insufficiency and HF) and in experimental models (obesity),
the heart becomes more sensitive to the effect of cardiac glycosides, due to a decrease in
NaC/KC-ATPase levels. The primary female sex steroid estradiol has long been recognized to
be important in a wide variety of physiological processes. Numerous studies, including ours,
have shown that estradiol is one of the major factors controlling the activity and expression
of NaC/KC-ATPase in the cardiovascular (CV) system. However, the effects of estradiol on
NaC/KC-ATPase in both normal and pathological conditions, such as obesity, remain unclear.
Increasing our understanding of the molecular mechanisms by which estradiol mediates its
effects on NaC/KC-ATPase function may help to develop new strategies for the treatment of
CV diseases. Herein, we discuss the latest data from animal and clinical studies that have
examined how pathophysiological conditions such as obesity and the action of estradiol
regulate NaC/KC-ATPase activity.Key Words
" estradiol
" sodium/potassium
adenosine triphosphatase
" obesity
" cardiovascular diseasesJournal of Endocrinology
(2013) 218, R13–R23IntroductionSodium/potassium-ATPase (NaC/KC-ATPase) is a membrane
protein responsible for the active transport of NaC and KC
ions across the plasma membranes of most higher
eukaryotes (Therien & Blostein 2000, Kaplan 2002). The
energy for this transport is derived from the hydrolysis ofthe terminal phosphate bond of ATP, during which the
acyl phosphate intermediate is formed, a hallmark of the
diverse membership of the P-type ATPase family (Kaplan
2002). A reduction in NaC/KC-ATPase levels is associated
with obesity, apparently linked to hyperglycemic
Jo
u
rn
a
l
o
f
E
n
d
o
cr
in
o
lo
g
y
Review M OBRADOVIC and others NaC/KC-ATPase, obesity, and
estradiol
218 :3 R14hyperinsulinemia, which may repress or inactivate the
enzyme (Fig. 1; Iannello et al. 2007a,b). A decrease in cardiac
NaC/KC-ATPase activity or protein concentration contrib-
utes to the deficiencies in cardiac contractility in animal
models and has been documented in patients with heart
failure (HF; Schwinger et al. 2003, Liu et al. 2012). The
majority of hormones (e.g. insulin, estradiol, aldosterone,
thyroid hormone, catecholamines, and glucocorticoids)
exert a positive effect on NaC/KC-ATPase by increasing its
activity or synthesis of new alpha (a)- and beta (b)-
subunits as well as by activating specific signaling cascades
(Ewart & Klip 1995, Dzurba et al. 1997, Devarajan & Benz
2000, Al-Khalili et al. 2004, Liu et al. 2007).
The primary female sex steroid estradiol has long been
recognized as an important hormone in a wide variety of
physiological processes (Knowlton & Lee 2012). Epide-
miological and retrospective studies have provided
important evidence for the diverse roles of estradiol in
human physiology and disease (Barros & Gustafsson 2011,
Burns & Korach 2012). Premenopausal women are
protected against cardiovascular (CV) diseases, while
postmenopausal women have the same risk for this disease
as men do (Rosano & Fini 2002, Katsiki et al. 2011c).
Obviously, estradiol deficiency plays a key role. Also, after
menopause when estradiol levels are decreased, lipid
accumulation and visceral fat mass are increased, which
all lead to an increased risk for the development of CV
diseases (Geer & Shen 2009). One of the cardioprotective
mechanisms proposed for estradiol involves its ability to
increase the activity and expression of NaC/KC-ATPase
in vitro (Dzurba et al. 1997, Isenovic et al. 2002, Sudar et al.
2008). Numerous studies, including ours, have shown that
estradiol is one of the major regulators of NaC/KC-ATPase
in the CV system (Dzurba et al. 1997, Isenovic et al. 2002,Activity ↑ Expression ↑
FFA ↑CGs
Leptin ↑[K+]i ↓
IR[Na+]i ↑
Hormones
Na+/K+-ATPase
Translocation ↑
PKC PKG ERK1/2PKBPKA
ObesityEnvironmental factors
Figure 1
NaC/KC-ATPase regulation in normal condition and obesity. PKA, protein
kinase A; PKB, protein kinase B; PKC, protein kinase C; PKG, protein
kinase G; [NaC]i, intracellular Na
C; [KC]i, intracellular K
C; CGs, cardiac
glycosides; IR, insulin resistance; FFAs, free fatty acids; upward arrow,
increased level; downward arrow, decreased level; upper and lower right
quadrants, inhibitory/reduction effect.
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DOI: 10.1530/JOE-13-0144 Printed in Great BritainPalacios et al. 2004). This explanation is also supported by
the observation that estradiol-induced increase in
NaC/KC-ATPase a2 expression leads to a significantly
higher activity of NaC/KC-ATPase (Palacios et al. 2004).
However, the mechanisms by which estradiol affects
NaC/KC-ATPase remain unclear, in both normal and
pathological conditions (such as obesity). Increasing our
understanding of the molecular mechanisms determining
the action of estradiol on NaC/KC-ATPase in humans may
help to develop new strategies for the treatment of CV
diseases, particularly in women. Therefore, in the present
review, we discuss the latest data from animal and clinical
studies focusing on the regulation of NaC/KC-ATPase in
pathophysiological conditions such as obesity and also the
effects of estradiol on the regulation of NaC/KC-ATPase.NaC/KC-ATPase: structure and function
The primary function of NaC/KC-ATPase is the mainten-
ance of low intracellular NaC and high intracellular KC
concentrations required for a multitude of cellular
functions. This occurs in several steps (Therien & Blostein
2000, Kaplan 2002). Following binding of ATP to NaC/KC-
ATPase, three NaC ions from the cytoplasm associate with
the molecule. The transfer of a phosphate group (via the
hydrolysis of ATP) to NaC/KC-ATPase results in a
conformational change that creates an opening outside
the cell that allows the three bound NaC ions to be
released. Two extracellular KC ions then bind, which
following cleavage of the phosphate group are released
inside the cell (Therien & Blostein 2000, Kaplan 2002,
Shinoda et al. 2009).
The NaC/KC-ATPase molecule is a hetero-oligomer
composed of a- and b-subunits, in a 1:1 ratio (Therien &
Blostein 2000, Kaplan 2002). In addition, other proteins
such as a family of seven homologous single trans-
membrane segment proteins (FXYD), which are often
referred to as g-subunits, contribute to the stabilization
and attenuation of NaC/KC-ATPase function (Fig. 2; Garty
& Karlish 2006). The large catalytic a-subunit (molecular
weight 110 kDa) contains binding sites for NaC and KC
ions and cardiac glycosides (CGs; Therien & Blostein 2000,
Kaplan 2002). It also possesses the transient phosphoryl-
ation site, where the terminal phosphate of ATP is
attached to the protein via an aspartate369 residue
(Pedersen et al. 1996, Ziegelhoffer et al. 2000). The
a-subunit has ten transmembrane domains and two
large intracellular loops, oriented such that the amino
and carboxyl ends are located intracellularly (Fig. 2;
Ziegelhoffer et al. 2000, Morth et al. 2007). The ATPPublished by Bioscientifica Ltd.
2 K+
3 Na+
β-subunit
γ-subunit
α-subunit
Extracellular
Intracellular
Figure 2
Diagram showing the topological arrangement of a- (yellow), b- (orange),
and g- (green; FXYD) subunits in the P-type NaC/KC-ATPase. Drawn using
PDB:2ZXE (Shinoda et al. 2009). Full colour version of this figure available
via http://dx.doi.org/10.1530/JOE-13-0144.
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218 :3 R15binding sites are located in the larger cytoplasmic loop
(Kaplan 2002). The a-subunit has four isoforms (a1, a2, a3,
and a4) (Juhaszova & Blaustein 1997, Therien & Blostein
2000, Segall et al. 2001). While the a1-isoform is expressed
ubiquitously, the a2-isoform is expressed largely in the
brain, heart, and muscle, as well as in a number of other
tissues (Kaplan 2002, Dostanic-Larson et al. 2006). The a3-
isoform is found in neurons and ovaries, but it is also
present in white blood cells and heart of some species,
such as humans (Jewell & Lingrel 1991, Therien & Blostein
2000, Dostanic-Larson et al. 2006). The a4-isoform is
localized to the testis. It is specifically synthesized at the
spermatogenic stage and is required for sperm motility
(Fig. 3; Woo et al. 2000).α1 α2 α3 α4
Ubiquitously
expressed
Expressed in:
• brain
• heart
• muscle
• Na+
• K+
• CG
• Transient
 phosphorylation
Expressed in:
• neurons
• ovary
• leukocytes
• heart
Expressed in:
• testes
Binding sites for:
ca
Stabilize
α-subunit
4-isoforms
α-subunit
Na
Figure 3
Distribution and function of NaC/KC-ATPase subunits.
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DOI: 10.1530/JOE-13-0144 Printed in Great BritainDespite the fact that various a-isoforms share a high
degree of sequence identity (w85% identity) (Jewell &
Lingrel 1991, Blanco & Mercer 1998), it is still necessary to
distinguish between tissue-specific and isoform-specific
differences in relation to their functional properties
(Therien & Blostein 2000, Kaplan 2002). It has also been
shown in cardiac cells that different isoforms (a1 and a2)
can localize in different regions of the same cell (James
et al. 1999). This suggests that the different isoforms are
capable of carrying out specific functions.
The smaller and highly glycosylated b-subunit
(molecular weight 35–55 kDa) is required for the stabil-
ization of the a-subunit and, it is thought, may modulate
cation affinity (Therien & Blostein 2000, Kaplan 2002). In
vitro studies using purified proteins indicate that the
separation of a- and b-subunits results in a lack of
measurable enzyme activity (Xie et al. 1996). The
b-subunit acts as a chaperone to stabilize the correct
folding and delivery of the a-subunit to the membrane
(Kawamura & Noguchi 1991, Koksoy 2002). The b-subunit
has a short cytoplasmic tail, one transmembrane segment,
and a large, glycosylated extracellular segment (Fig. 2;
Beggah et al. 1997, Morth et al. 2007). Three isoforms of
the b-subunit exist (b1, b2, and b3) (Therien & Blostein
2000, Kaplan 2002). The b1-isoform is, similar to the
a1-isoform, ubiquitously expressed, suggesting a house-
keeping role for the a1b1 NaC/KC-ATPase in most cells
(Tokhtaeva et al. 2012). The b2-isoform is expressed
predominantly in the brain and muscle (Avila et al.
1998), while the b3-isoform is mainly expressed in the
lungs, testis, skeletal muscle, brain, and liver (Appel et al.
1996, Tokhtaeva et al. 2012). In human heart, a1-, a2-, andβ1 β2 β3 FXYD1 or
γ-subunit
FXYD2
Ubiquitously
expressed
Expressed in:
• brain
• muscle
• heart
Expressed in:
• lungs
• testes
• muscle
• brain
• liver
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218 :3 R16a3-isoforms are expressed together with the b1-isoform
and very low levels of b2-isoform in a region-specific
manner (Fig. 3; Schwinger et al. 1999, 2003).
The FXYD proteins are a family of seven homologous
single transmembrane segment proteins (FXYD1–7), termed
after the invariant FXYD amino acid motif in their
extracellular domain (Fig. 2; Sweadner & Rael 2000,
Garty & Karlish 2006). They act as tissue-specific
regulatory subunits, which adjust the kinetic properties of
NaC/KC-ATPase to the needs of the particular cell type
or physiological state (Garty & Karlish 2006). FXYD1
(or phospholemman) is mainly expressed in the heart and
skeletal muscle (Chen et al. 1997, Lifshitz et al. 2006, Geering
2008); its regulation is important for NaC/KC-ATPase
function, especially in CV diseases. In addition, FXYD2,
initially referred to as the g-subunit, has been shown to be
predominantly expressed in the kidneys (Fig. 3; Forbush et al.
1978, Kim et al. 1997, Garty & Karlish 2006). Later studies
have described other g-subunits that belong to the same
family of proteins but expressed in other tissues (Garty &
Karlish 2006, Geering 2008). However, to our knowledge,
these are not known to be important for the regulation of
NaC/KC-ATPase in the CV system.
It has been reported that the four a-subunit and three
b-subunit isoforms of NaC/KC-ATPase are encoded by
different genes and are synthesized independently of
each other (Lingrel & Kuntzweiler 1994, Jorgensen et al.
2003). The isoforms combine to form a number of
NaC/KC-ATPase isozymes expressed in a tissue-specific
and cell-specific manner (Jorgensen et al. 2003). The
heterodimeric protein subunits are synthesized indepen-
dently in the endoplasmic reticulum and assembly during
or very soon after synthesis in this organelle (Geering et al.
1996, Therien & Blostein 2000, Efendiev et al. 2007).
The concentration of NaC/KC-ATPase in tissues
varies greatly; a large difference exists between the lowest
(i.e. 250–500 sites/cell in erythrocytes) and the highest
(i.e. 11 000–12 000 pmol/g wet weight in the brain cortex)
measured concentrations (Lauf & Joiner 1976, Wiley &
Shaller 1977, Schmidt et al. 1992, 1996, Koksoy 2002). A
number of studies comparing different heterologously
expressed human NaC/KC-ATPase isoforms have been
conducted. Two studies revealed that ouabain had a
twofold lower affinity for the a2b1-heteromer than for
the a1b1- or a3b1-heteromer (Crambert et al. 2000,
Muller-Ehmsen et al. 2001, Schwinger et al. 2003). In
these studies, examining the apparent affinity for NaC and
KC yielded conflicting results. The effects of NaC and KC
on equilibrium ouabain binding were measured to
estimate the affinity of NaC/KC-ATPase for these cations.http://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0144 Printed in Great BritainThe apparent affinities of NaC and KC were measured as
the half-activation constant for NaC and KC (K0.5), which
is different from the intrinsic affinity (Km) (Jaisser et al.
1994). K0.5 values (concentration of ligand that yields the
half-maximal response) for NaC and KC were obtained
from the NaC and KC antagonism of equilibrium ouabain
binding. In one study, affinities for NaC were found to be
similar for all the cardiac heteromers (Muller-Ehmsen et al.
2001), while in another study a1b1-heteromer had the
highest affinity for NaC and the a3b1-heteromer had the
lowest affinity (Crambert et al. 2000). Affinities toward KC
were similar for the a1b1- and a3b1-heteromers, but the
affinity of the a2b1-heteromer was significantly lower in
one study (Muller-Ehmsen et al. 2001), while in another
study affinities toward KC were found to be similar for
these heteromers (Crambert et al. 2000).Regulation of NaC/KC-ATPase in
physiological and pathophysiological
conditions
Hormones and environmental factors can regulate
NaC/KC-ATPase activity through i) gene expression,
ii) trafficking, and iii) phosphorylation (Ewart & Klip
1995, Isenovic et al. 2004a,b, Efendiev et al. 2007, Li et al.
2011). The first mechanism is through the regulation of
gene transcription, generally occurring over days (Bonvalet
1998, Therien & Blostein 2000). The second mechanism of
regulation is that new NaC/KC-ATPase subunits are
delivered to the plasma membrane from intracellular
stores when needed (Hundal et al. 1992, Al-Khalili et al.
2003). It has been shown that NaC/KC-ATPase-containing
compartments are located just underneath the plasma
membrane (Efendiev et al. 2007). Regulation performed
through direct effects on the kinetic behavior of the
enzyme occurs within minutes to hours and is accom-
plished through changes in the turnover rate of the
existing pumps via the phosphorylation of protein kinase
A (PKA), PKC, PKB, or PKG (Fig. 1; Bertorello & Katz 1993,
Li et al. 1999, Therien & Blostein 2000, Sudar et al. 2008).
The third proposed mechanism includes regulation
through direct effects on the kinetic behavior of the
pumps that are already present in the membrane, which
occurs within minutes to hours (Therien & Blostein 2000).
Despite this, it is important to point out that this mechanism
is controversial (Chibalin et al. 1998, 1999, Fuller et al. 2004,
2013, Despa et al. 2005, Silverman et al. 2005).
NaC/KC-ATPase is the specific target for the action of
digitalis and other CGs. These are produced in mammals
in a manner similar to the production of steroid hormonesPublished by Bioscientifica Ltd.
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218 :3 R17from cholesterol and act as indirect regulators of cardiac
contractility (positive inotropy) (Bagrov et al. 2009,
Lingrel 2010). CGs bind to the extracellular part of
NaC/KC-ATPase to inhibit its activity (Kaplan 2002,
Lingrel 2010); it is widely accepted that one ouabain
binds to one ab heteromer (Kaplan 2002). Thus, the
inhibition of NaC/KC-ATPase in myocytes by endogenous
CGs leads, at least locally, to an increased NaC concen-
tration, followed by increased intracellular Ca2C levels (via
NaC,Ca2C-exchangers) (Bagrov et al. 2009, Lingrel 2010).
This rise in intracellular Ca2C content triggers the release
of Ca2C from the sarcoplasmic reticulum, resulting in
increased heart contraction (Grupp et al. 1985, Bagrov
et al. 2009). Besides this, there is growing evidence that
non-inhibitory doses of ouabain can modulate cell
proliferation, apoptotic threshold, cell-to-cell contact,
and cell migration (Aperia 2007). These effects generally
require the binding of ouabain to NaC/KC-ATPase and
then NaC/KC-ATPase can function as a signal transducer
(Aperia 2007). Several years ago, Aperia’s group made the
observation that ouabain triggered NaC/KC-ATPase-
dependent activation of the inositol 1,4,5-trisphosphate
receptor (IP3R) via a direct interaction (Aizman et al. 2001,
Khodus et al. 2011). The activation of IP3R results in
oscillatory increases in intracellular Ca2C content (Aizman
et al. 2001, Aperia 2007). Ca2C oscillations have emerged
as the most versatile of all cell signals, as the cell can
decode the frequency of the oscillations (Berridge 2007).
Ca2C oscillations generated by the NaC/KC-ATPase–IP3R
complex have a low frequency and activate the pleiotropic
transcriptional factor nuclear factor kappa B (NFkB), which
protects from apoptosis (Li et al. 2006, Khodus et al. 2011).
During several pathological situations (cardiac insuffi-
ciency and HF) and in obesity experimental models, the
heart becomes more sensitive to the effect of CGs due to a
decrease in the number of NaC/KC-ATPase molecules
(Shamraj et al. 1993, Koksoy 2002, Liu et al. 2012).
Therefore, the regulation of NaC/KC-ATPase activity and
expression may be important for the treatment and
possible prevention of these diseases (Fig. 1; Koksoy 2002).
The expression of NaC/KC-ATPase isoforms is
regulated with high specificity in different regions of the
heart during both physiological and pathophysiological
states. In normal human left ventricular (LV) myocardium,
a NaC/KC-ATPase concentration of w700 pmol/g wet
weight can be found (Schmidt et al. 1993, Schwinger
et al. 2003). Also, in normal human right atrium,
NaC/KC-ATPase activity is 40% lower vs that in LV
myocardium (Schwinger et al. 2003, Wencker et al.
2003). Several studies have reported a consistent andhttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0144 Printed in Great Britainsignificant decrease of 26–32% in NaC/KC-ATPase protein
content in human HF (Norgaard et al. 1988, Schwinger
et al. 1990, 2003). Data show that the inhibition of cardiac
myocyte death largely prevents the development of
cardiac dilation and contractile dysfunction (Wencker
et al. 2003), i.e. the hallmarks of HF. Recently, it has been
found that a reduction in NaC/KC-ATPase levels in cardiac
tissue induces myocyte death and cardiac dysfunction (Liu
et al. 2012), thus possibly leading to the development of
myocardial dilation and HF. Norgaard et al. (1988) also
reported that decreased NaC/KC-ATPase concentration
may be of importance for myocardial dysfunction and
dilated cardiomyopathy. They enrolled 24 patients with
suspected idiopathic dilated cardiomyopathy in their
study (Norgaard et al. 1988). Nineteen patients had
impaired LV function and a NaC/KC-ATPase concen-
tration of 331G19 pmol/g wet weight, whereas five
patients had normal LV function and a NaC/KC-ATPase
concentration of 559G62 pmol/g wet weight (P!0.001)
(Norgaard et al. 1988).
In heart tissue biopsies from patients with dilated
cardiomyopathy, total NaC/KC-ATPase concentration is
decreased by up to 40% (Norgaard et al. 1988). Semb et al.
(1998) examined changes in cardiac NaC/KC-ATPase
expression and function in a post-infarction rat model of
hypertrophy and congestive HF (CHF). They found that in
the CHF group the ratio of heart weight to body weight
was 70% greater than that in the control group (P!0.05).
Also, the expression of the a1- and b1-subunits (mRNA
and protein) of the NaC/KC-ATPase was not significantly
different in the CHF and control groups, but mRNA and
protein levels of the a2-isoform were lower in the hearts of
the CHF group by 25 and 55% respectively; mRNA levels
of the a3-isoform were higher by 120% and cell volume of
the isolated cardiomyocytes was 30% larger in the CHF
group than in the control group (Semb et al. 1998). Allen
et al. (1992) found no significant alteration in mRNA
expressions of the isoforms, but total NaC/KC-ATPase
concentration was non-significantly reduced byw10% in
patients with end-stage HF due to either ischemic or
dilated cardiomyopathy, compared with the normal
controls. Shamraj et al. (1993) reported for the first time
that failing human hearts are more sensitive to ouabain,
due to a mean reduction of 42% in NaC/KC-ATPase
concentration. Schwinger et al. (1999) showed that
the reduction of the expression and activity of
NaC/KC-ATPase protein enhanced the sensitivity of
failing human myocardium toward CGs; at the protein
level, a1- and a3-isoform levels were lower (by K38 and
K30% respectively) in failing human myocardium thanPublished by Bioscientifica Ltd.
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b1-isoform, maximal ouabain binding, and NaC/KC-
ATPase activity were lower (by K39, K39, and K42%
respectively), while the expression of the a2-isoform
showed only a small tendency toward reduction
(Schwinger et al. 1999, 2003).Regulation of NaC/KC-ATPase by estradiol
Several studies have shown that estradiol is one of the
primary NaC/KC-ATPase regulators in the CV system
(Dzurba et al. 1997, Isenovic et al. 2002, Palacios et al. 2004,
Li et al. 2011). This finding is also supported by the obser-
vation that estradiol-induced increase in NaC/KC-ATPase a2
expression leads to a significantly higher NaC/KC-ATPase
activity (Palacios et al. 2004). Estradiol has also been
reported to enhance NaC/KC-ATPase activity in H9C2
cardiac myocytes and rat hearts (Liu et al. 2007, 2012).
By contrast, ovariectomized rats exhibited a decreased
NaC/KC-ATPase activity (Kaur et al. 1997, Li et al. 2011).
In women, NaC/KC-ATPase activity in erythrocytes
increased when estradiol levels reached their peak during
the menstrual cycle (Melis et al. 1990).
Estradiol exerts these effects through the activation of
multiple signaling cascades. One studied mechanism of
the activation of NaC/KC-ATPase includes phosphatidyl-
inositol 3-kinase (PI3K) and PKB (Akt) (Isenovic et al.
2002, 2004b, Sudar et al. 2008). The activation of PI3K and
Akt also plays an important role in the heart through the
regulation of the survival and function of cardiomyocytes
(Huang & Kaley 2004, Matsui & Rosenzweig 2005). It has
also been reported that premenopausal women display a
significantly greater staining of Akt in the nuclei of cardiac
myocytes than men or postmenopausal women (Camper-
Kirby et al. 2001, Sugden & Clerk 2001). Also, elevated
nuclear phospho-Akt473 localization in cultured cardio-
myocytes after exposure to estradiol or the phytoestrogen
genistein has also been shown (Camper-Kirby et al. 2001,
Huang & Kaley 2004). The activation of Akt in a gender-
dependent manner may help explain functional benefits
for the heart provided by estrogenic stimulation and also
differences in CV disease risks between the sexes
(Camper-Kirby et al. 2001). In the CV system, the
activation of estrogen receptor a (ERa) by estradiol has
been shown to activate PI3K through the binding of
phosphotyrosine-containing proteins such as insulin
receptor substrate-1 (IRS1) and IRS2 and the association
of p85 with IRS1 in different types of cells (Mauro et al.
2001, Isenovic et al. 2003, Sudar et al. 2008, Koricanac et al.
2009). Some authors, including our team, have alreadyhttp://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0144 Printed in Great Britaindescribed an inducing effect of estradiol on Akt serine
(Ser473) phosphorylation, but data concerning threonine
(Thr308) are rare (Ren et al. 2003, Patten et al. 2004,
Koricanac et al. 2011).
Our previously published results together with others
indicated that ERK1/2 are involved in the regulation of
NaC/KC-ATPase (Al-Khalili et al. 2004, Isenovic et al.
2004a). We have shown that the ERK1/2 inhibitor
PD98059 abrogates the stimulation of NaC/KC-ATPase
activity, suggesting the involvement of ERK1/2 signaling
as well (Isenovic et al. 2004a). Estradiol has been reported
to rapidly activate ERK1/2, resulting from more proximal
kinase activation, including Ras, Src, raf, and MEK
stimulation (Migliaccio et al. 1996, Levin 2001, Koricanac
et al. 2011).
Some of the effects of estradiol have been linked to the
activity of high-molecular-weight (85 kDa) cytosolic
phospholipase A2 (cPLA2; Burlando et al. 2002, Sudar
et al. 2008), which is also abundantly expressed in the heart
and vasculature (LaPointe & Isenovic 1999, Murakami &
Kudo 2002, Sudar et al. 2008). Evidence that cPLA2 plays
a role in the regulation of NaC/KC-ATPase activity includes
a report that the inhibition of NaC/KC-ATPase activity is
mediated by the activation of cPLA2 (Xia et al. 1995).
However, to our knowledge, a direct correlation between
estradiol-induced activation of cPLA2 and Na
C/KC-ATPase
regulation has not been established yet. Maximal activation
of cPLA2 requires sustained dual phosphorylation of Ser
505
and Ser727 by MAPKs and MAPK-activated protein kinases
respectively (Lin et al. 1993, Murakami & Kudo 2002,
Sudar et al. 2008). Other kinases have been shown to
phosphorylate cPLA2, including the stimulation of ERK1/2
(van Rossum et al. 2001, Sudar et al. 2008).
The results presented by Li et al. (2011) indicated that
estradiol may influence both the specific activity and
physiological function of the cardiac NaC/KC-ATPase and
these effects may participate in the reported protective
influence of the hormone against myocardial ischemia.
Using a yeast two-hybrid assay, NaC/KC-ATPase
b1-subunits have been identified as potential binding
partners for N-myc downstream-regulated gene 2
(NDRG2). NDRG2 is a cytoplasmic protein and member
of the NDRG family (Deng et al. 2003, Hu et al. 2006,
Li et al. 2011). It has been reported that human NDRG2 is
expressed in many tissues, especially in the brain, heart,
skeletal muscle, and kidneys, where NaC/KC-ATPase is
enriched (Hu et al. 2006, Li et al. 2011). Analysis of
the promoter region flanking 5 0 of the NDRG2 gene
revealed a putative estrogen-response element in the
region (5 0-nnAGTCAnnnTGACCnn-3 0), which suggestsPublished by Bioscientifica Ltd.
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expression of NDRG2 (Li et al. 2011).
Estradiol has been reported earlier to improve the
excitation contraction coupling and maintenance of
cation homeostasis in cardiac myocytes via the stimu-
lation of the NaC/KC-ATPase activity of cardiac sarcolem-
mal membranes (Dzurba et al. 1997, Barta et al. 1989). In
addition, it was speculated by Dzurba et al. (1997) that
estradiol may interact with the enzyme molecule at least
in three different ways:
(i) Directly – whereby a chemical modification of the
enzyme molecule may be responsible for the
observed effects (Kamernitskii et al. 1982).
(ii) Through the digitalis receptor – in this case, the
action may be based on some structural similarities
between the molecules of digitalis and that of
estradiol (Franck et al. 1984).
(iii) Through a Ca2C-dependent protein kinase-
mediated phosphorylation mechanism – where
the enzyme molecule may be activated by phos-
phorylation to bind to estradiol (Migliaccio et al.
1982, Dzurba et al. 1997, Sudar et al. 2008).NaC/KC-ATPase and obesity
In obese patients, NaC/KC-ATPase activity is reduced in
adipose tissue and negatively correlated with BMI, oral
glucose tolerance test, and blood pressure (Iannello et al.
2007a,b). Obesity is associated with tissue NaC/KC-ATPase
reduction, apparently linked to hyperglycemic
hyperinsulinemia, which may repress or inactivate the
enzyme (Iannello et al. 2007a,b). Also, obesity is associated
with a reduction of NaC/KC-ATPase activity in both
humans and rodents (Iannello et al. 2007a,b). Bray and
Yukimura reported decreased NaC/KC-ATPase activity in
the liver of animals with experimental obesity (Bray &
Yukimura 1978). Furthermore, Lin et al. (1978, 1981) have
shown that the protein levels of NaC/KC-ATPase subunits
are lower in the skeletal muscle and liver of adult obese
(ob/ob) mice than in those of their lean counterparts,
probably due to the decrease in the number of enzyme
units. This, of course, cannot be due to an inhibitory effect,
but could be the result of a repressing effect (Iannello et al.
2007a). In this context, Guernsey & Morishige (1979) have
also shown the reduction of NaC/KC-ATPase activity in
ob/ob mice (Fig. 1).
As with laboratory rodent models, human obesity is
associated with reduced NaC/KC-ATPase activity in
some tissues (Iannello et al. 2007a,b). Insulin resistance,http://joe.endocrinology-journals.org  2013 Society for Endocrinology
DOI: 10.1530/JOE-13-0144 Printed in Great Britaina phenomenon common in obesity, may repress
NaC/KC-ATPase enzyme activity, probably through the
mediation of free fatty acids (FFAs), which are elevated in
such cases (Iannello et al. 2007a,b). FFAs, present in
the membrane or as the products of phospholipase A2
(PLA2)-dependent regulatory pathway, tend to inhibit
NaC/KC-ATPase (Oishi et al. 1990, Therien & Blostein
2000). Interestingly, Iannello et al. (1994) reported that
NaC/KC-ATPase activity is reduced in the adipose tissue of
obese hyperinsulinemic subjects (Fig. 1).
Obesity as well as diabetes is associated with
hyperleptinemia in the presence of leptin resistance;
various drugs frequently prescribed to such patients
may also affect leptin levels (Katsiki et al. 2011a,b,
Paspala et al. 2012). Leptin has been shown to decrease
NaC/KC-ATPase activity in rat kidney via the PI3K
pathway (Fig. 1; Beltowski et al. 2004). Impaired
NaC/KC-ATPase function has also been observed in
diabetes, hypertension, dyslipidemia, and metabolic
syndrome (Koter et al. 2004, Chibalin 2007, Rodrigo
et al. 2007, Javorkova et al. 2010). Interestingly, both
metformin and statins have been reported to enhance
the NaC/KC-ATPase activity of erythrocytes in diabetic
and dyslipidemic patients respectively (Chakraborty
et al. 2011, Uydu et al. 2012). Similarly, antihyperten-
sive agents (i.e. losartan and enalapril) attenuated the
decreased activity of sarcolemmal NaC/KC-ATPase in
the failing heart of rats after myocardial infarction (Guo
et al. 2008). Further studies are needed to investigate
the impact of such CV risk-reducing drugs on NaC/KC-
ATPase function.Conclusions
Reduced NaC/KC-ATPase function seems to play a
causal role in the development of CV diseases, probably
due to the association of decreased NaC/KC-ATPase
activity with other risk factors (e.g. obesity or impaired
estradiol signaling). Thus, the regulation of NaC/KC-
ATPase activity and expression as well as the regulation
of different NaC/KC-ATPase isoforms may be important
for the treatment and possible prevention of CV
diseases. Despite many available data, the effects of
estradiol on NaC/KC-ATPase still remain unclear, in
both normal and pathological conditions, such as
obesity. Increasing our understanding of the molecular
mechanisms determining the action of estradiol on
NaC/KC-ATPase in humans may help to develop new
strategies for the treatment of CV diseases in women
and possibly also in men.Published by Bioscientifica Ltd.
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